A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

Registration Number
NCT05980806
Lead Sponsor
Karyopharm Therapeutics Inc
Brief Summary

The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
118
Inclusion Criteria
  • A diagnosis of MF or post-ET or post-PV MF according to the 2016 World Health Organization (WHO) classification of MPN, confirmed by the most recent local pathology report.
  • Measurable splenomegaly during the screening period as demonstrated by spleen volume of greater than equal to (>=) 450 cubic square centimeter (cm^3) by MRI or CT scan (results from MRI or CT imaging performed within 28 days prior to screening are acceptable).
  • Participants with DIPSS risk category of intermediate-1 with symptoms, or intermediate-2, or high-risk.
  • ECOG Performance Status less than or equal to (<=) 2.
  • Platelet count of 50 to less than (<) 100 x 10^9/L without platelet transfusion within 7 days prior to the first dose of selinexor.
  • Absolute neutrophil count (ANC) >=1.0 × 10^9/L without need for growth factors within 7 days prior to the first dose of selinexor.
  • Adequate liver function as defined by the following: aspartate transaminase (AST) and alanine aminotransferase (ALT) <= 2.5 × upper limit normal (ULN) and serum total bilirubin <= 3×ULN.
  • Calculated creatinine clearance (CrCl) greater than (>) 15 milliliter per minute (mL/min) based on the Cockcroft and Gault formula.
  • Active symptoms of MF as determined by presence of at least 2 symptoms with a score >= 3 or total score of >= 10 at screening using the MFSAF V4.0.
  • Participants must provide bone marrow biopsy samples (samples obtained up to 3 months prior to C1D1 are permitted) at screening and during the study.
  • Participants currently not a candidate for stem cell transplantation.
  • Participants must be willing to complete the MFSAF V4.0 daily during the study for evaluating the symptom response (i.e., TSS50).

Key

Read More
Exclusion Criteria
  • More than 10% blasts in peripheral blood or bone marrow (accelerated or blast phase).
  • Previous treatment with JAK inhibitors for MF.
  • Previous treatment with selinexor or other XPO1 inhibitors.
  • Female participants who are pregnant or lactating.
  • Prior splenectomy, or splenic radiation within 6 months prior to C1D1.
  • History of myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG), cerebrovascular accident (stroke or transient ischemic attack [TIA]), ventricular arrhythmias, congestive heart failure New York Heart Association (NYHA) class > 2 within 6 months of C1D1.
  • Participants unable to tolerate two forms of antiemetics prior to each dose for the first two cycles.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Selinexor 60 mg (Arm 1)Selinexor 60 mgParticipants will receive selinexor 60 milligrams (mg) oral tablets once weekly (QW) (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on Spleen Volume Reduction (SVR) values.
Selinexor 40 mg (Optional Expansion Arm)Selinexor 40 mgParticipants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is \<10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets \>= 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 g/dL).
Selinexor 40 mg (Arm 2)Selinexor 40 mgParticipants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on SVR values.
Selinexor 60 mg (Optional Expansion Arm)Selinexor 60 mgParticipants will receive selinexor 60 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is less than (\<) 10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets greater than or equal to \[\>=\] 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 gram per deciliter \[g/dL\]).
Selinexor 60 mg (Optional Expansion Arm)MomelotinibParticipants will receive selinexor 60 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is less than (\<) 10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets greater than or equal to \[\>=\] 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 gram per deciliter \[g/dL\]).
Selinexor 40 mg (Optional Expansion Arm)RuxolitinibParticipants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is \<10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets \>= 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 g/dL).
Selinexor 40 mg (Optional Expansion Arm)PacritinibParticipants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is \<10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets \>= 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 g/dL).
Selinexor 60 mg (Arm 1)RuxolitinibParticipants will receive selinexor 60 milligrams (mg) oral tablets once weekly (QW) (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on Spleen Volume Reduction (SVR) values.
Selinexor 60 mg (Arm 1)PacritinibParticipants will receive selinexor 60 milligrams (mg) oral tablets once weekly (QW) (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on Spleen Volume Reduction (SVR) values.
Selinexor 60 mg (Arm 1)MomelotinibParticipants will receive selinexor 60 milligrams (mg) oral tablets once weekly (QW) (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on Spleen Volume Reduction (SVR) values.
Selinexor 40 mg (Arm 2)RuxolitinibParticipants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on SVR values.
Selinexor 40 mg (Arm 2)PacritinibParticipants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on SVR values.
Selinexor 40 mg (Arm 2)MomelotinibParticipants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first and followed by optional add-on medication dosing may be initiated based on SVR values.
Selinexor 60 mg (Optional Expansion Arm)RuxolitinibParticipants will receive selinexor 60 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is less than (\<) 10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets greater than or equal to \[\>=\] 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 gram per deciliter \[g/dL\]).
Selinexor 60 mg (Optional Expansion Arm)PacritinibParticipants will receive selinexor 60 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is less than (\<) 10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets greater than or equal to \[\>=\] 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 gram per deciliter \[g/dL\]).
Selinexor 40 mg (Optional Expansion Arm)MomelotinibParticipants will receive selinexor 40 mg oral tablets QW (Days 1, 8, 15, and 22 of each 28-day cycle) until PD, intolerable toxicity, or until they meet the criteria for discontinuation of study treatment, death, or withdrawal of consent, whichever comes first. Optional add-on medication (ruxolitinib \[5 mg or 10 mg twice daily\], pacritinib \[200 mg twice daily\], or momelotinib \[200 mg once daily\]) may be initiated for participants whose SVR is \<10% at Week 12 or \<35% at Week 24 based on the participants platelet count values (i.e., ruxolitinib if platelets \>= 50 x 10\^9/L, pacritinib if platelets \<50 x 10\^9/L, momelotinib if platelets is \>=50 x 10\^9/L and hemoglobin level is \< 10 g/dL).
Primary Outcome Measures
NameTimeMethod
Proportion of Participants with Spleen Volume Reduction 35 (SVR35) at Week 24.At Week 24

Measured by Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) Scan

Secondary Outcome Measures
NameTimeMethod
Proportion of Participants with Total Symptom Score 50 (TSS50) at Week 24.At Week 24

Measured by the Myelofibrosis Symptom Assessment Form (MFSAF) V4.0. A higher Total Symptom Score (TSS) indicates a higher disease burden and thus a worse outcome.

Proportion of Participants with Anemia Response at Week 24 as per the International Working Group Myeloproliferative Neoplasms Research and Treatment and European Leukemia Network (IWG-MRT and ELN) CriteriaAt Week 24
TSS50 Response in Pre-specified MF Participant Subgroups (Including by Gender, Age, and Geographic Region)From Baseline up to EoS (approximately 48 months)
SVR35 Response in Participants who Receive as add-on Treatments (Ruxolitinib or Pacritinib or Momelotinib) to Selinexor and Single-agent Selinexor OnlyAt Week 24
Proportion of Participants with SVR35 at Any Time Point.From Baseline to EoS (approximately 48 months)

Measured by MRI or CT Scan.

Anemia Response in Pre-specified MF Participant Subgroups (Including by Gender, Age, and Geographic Region)From Baseline up to EoS (approximately 48 months)
TSS50 Response in Participants who Receive as add-on Treatments (Ruxolitinib or Pacritinib or Momelotinib) to Selinexor and Single-agent Selinexor OnlyAt Week 24
Number of Participants with TEAEs, Severity of TEAEs, TRAEs and SAEs in Participants who Receive as add-on Treatments (Ruxolitinib or Pacritinib or Momelotinib) to Selinexor and Single-agent Selinexor OnlyFrom start of drug administration up to 30 days after the last dose of study treatment (approximately 48 months)
Proportion of Participants with Post-treatment Changes in Bone MarrowFrom Baseline up to EoS (approximately 48 months)
Number of Participants with Treatment-emergent Adverse Events (TEAEs), Severity of TEAEs, Treatment Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)From start of drug administration up to 30 days after the last dose of study treatment (approximately 48 months)
Overall Survival (OS)From date of randomization to the date of death due to any cause or EoS (assessed at approximately 48 months)
Overall Response Rate (ORR) as per IWG MRT and ELN CriteriaFrom Cycle 1 Day 1 (28-day cycle) up to EoS (approximately 48 months)
Proportion of Participants with TSS50 at Any Time.From Baseline to EoS (approximately 48 months)

Measured by the MFSAF V4.0. A higher Total Symptom Score (TSS) indicates a higher disease burden and thus a worse outcome.

SVR35 Response in Pre-specified MF Participant Subgroups (Including by Gender, Age, and Geographic Region)From Baseline up to EoS (approximately 48 months)
Anemia Response in Participants who Receive as add-on Treatments (Ruxolitinib or Pacritinib or Momelotinib) to Selinexor and Single-agent Selinexor OnlyAt Week 24
Area Under the Concentration-time Curve (AUC) of SelinexorPre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and 2 hours post-dose on Cycle 2 Day 15 (28-day cycle)
Maximum Plasma Concentration (Cmax) of SelinexorPre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and 2 hours post-dose on Cycle 2 Day 15 (28-day cycle)
Time at Which Cmax is Achieved (Tmax) of SelinexorPre-dose, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Cycle 1 Day 15 and 2 hours post-dose on Cycle 2 Day 15 (28-day cycle)
Duration of Receptor Occupancy or Exportin 1 (XPO1) mRNA InductionFrom Baseline up to EoS (approximately 48 months)

Trial Locations

Locations (21)

Duke University

🇺🇸

Durham, North Carolina, United States

Huntsman Cancer Institute

🇺🇸

Salt Lake City, Utah, United States

UZ Gent

🇧🇪

Gent, Belgium

UZ Leuven - Campus Gasthuisberg

🇧🇪

Leuven, Belgium

University Multiprofile Hospital for Active Treatment Aleksandrovska

🇧🇬

Sofia, Bulgaria

Specialized Hospital for Active Treatment of Hematological Diseases - EAD Sofia

🇧🇬

Sofia, Bulgaria

University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD Department of Clinical Hematology

🇧🇬

Stara Zagora, Bulgaria

Marien Hospital Düsseldorf

🇩🇪

Düsseldorf, Germany

University Hospital Jena

🇩🇪

Jena, Germany

Spaarne Gasthuis

🇳🇱

Hoofddorp, Netherlands

Coltea - Spital Clinic

🇷🇴

Bucharest, Romania

Spitalul Filantropia - Craiova

🇷🇴

Craiova, Romania

Hospital Clínico Universitario Virgen de la Arrixaca

🇪🇸

El Palmar, Murcia, Spain

Institut Català d'Oncologia Girona

🇪🇸

Girona, Spain

Hospital Universitario de Gran Canaria Doctor Negrin

🇪🇸

Las Palmas De Gran Canaria, Spain

Complejo Asistencial Universitario de Salamanca - Hospital Clínico

🇪🇸

Salamanca, Spain

City of Hope - Duarte Main Site

🇺🇸

Duarte, California, United States

Maryland Oncology Hematology - Independent of SCRI/ US Oncology

🇺🇸

Columbia, Maryland, United States

Weill Cornell Medicine NewYork-Presbyterian

🇺🇸

New York, New York, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

Research Institute of the McGill University Health Centre

🇨🇦

Montreal, Quebec, Canada

Related News

onclive.com
·

Selinexor Paves the Way for More Affordable, Effective Treatment Options in Myelofibrosis

Selinexor, an exportin 1 inhibitor, shows promise in myelofibrosis, with efficacy in combination with ruxolitinib and as a single agent. FDA fast track designation aims to address financial burdens and personalize therapy, with SENTRY-2 evaluating selinexor monotherapy in JAK inhibitor–naive patients. Scandura emphasizes the need to recognize myelofibrosis as a serious condition requiring effective, affordable treatments.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy